Cargando…
ML-02 MULTIAGENT IMMUNOCHEMOTHERAPY, R-MPV-A, FOR PATIENTS WITH SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
BACKGROUNDS: Standard of care (SOC) for primary central nervous system lymphoma (PCNSL) has been induction therapy with high-dose methotrexate (MTX)-based multiagent immunochemotherapies followed by consolidation, and we have shown that one such regimen, R-MPV-A have superior efficacy over HD-MTX al...
Autores principales: | Nagane, Motoo, Kobayashi, Keiichi, Saito, Kuniaki, Shimada, Daisuke, Matsumoto, Yoshie, Iijima, Shohei, Sasaki, Nobuyoshi, Yamagishi, Yuki, Takayama, Nobuyuki, Shiokawa, Yoshiaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213230/ http://dx.doi.org/10.1093/noajnl/vdz039.145 |
Ejemplares similares
-
ML-02 Chemotherapy for patients with relapsed or refractory primary CNS lymphoma
por: Nagane, Motoo, et al.
Publicado: (2020) -
ML-21 Tirabrutinib monotherapy for relapsed/refractory primary central nervous system lymphoma
por: Kobayashi, Keiichi, et al.
Publicado: (2020) -
ML-08 Safety and efficacy of consolidation cytarabine for newly-diagnosed primary central nervous system lymphoma
por: Sasaki, Nobuyoshi, et al.
Publicado: (2020) -
ML-18 High-dose chemotherapy supported by autologous stem cell transplant in relapsed and refractory primary CNS lymphoma
por: Nagane, Motoo, et al.
Publicado: (2021) -
COT-20 PERIOPERATIVE STATUS OF SERUM D-DIMER LEVEL AND VENOUS THROMBOSIS IN PATIENTS WITH MALIGNANT BRAIN TUMOR
por: Shimada, Daisuke, et al.
Publicado: (2019)